menu

CME: Treatment Options in Non-Type 2 Asthma

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Treatment Options in Non-Type 2 Asthma

close
0.25 credits
15 Minutes
Treatment Options in Non-Type 2 Asthma
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Comments
  • Overview

    Recent advances in asthma therapy have included several new biologic agents that modify Th2-inflammatory pathways. Treatment guidelines have provided a framework for the treatment of patients with Th2-mediated allergic asthma. However, approximately half of asthmatic patients do not fall within the Th2 inflammatory paradigm. Cinicians must be knowledgeable of treatment options and the role of potential novel therapies for this subgroup of patients.

  • Disclosure of Conflicts of Interest

    CHEST remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any relevant financial relationships that create a conflict of interest. It is not the intent of CHEST to disqualify anyone from participating in this educational activity, but to resolve any conflicts of interest that may arise from financial relationships with commercial interests. All conflicts of interest are reviewed by the educational activity course director/chair, the Education Committee, and/or the Professional Standards Committee to ensure that such situations are properly evaluated and, if necessary, resolved. CHEST educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all CHEST CME activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relevant financial relationships will be made available on-site during all educational activities.

    The following faculty members of this activity have disclosed to CHEST that they have a relevant financial relationship with a commercial interest as it relates to the activity:

    Host: Sandhya Khurana, MD, FCCP
    Professor of Medicine
    Division of Pulmonary & Critical Care Medicine
    Director, Mary Parkes Center for Asthma, Allergy & Pulmonary Care
    University of Rochester,
    Rochester, NY

    Financial Disclosure:
    Grant/Research Support: GlaxoSmithKline, AstraZeneca Pharmaceuticals LP, Sanofi; Editorial Support: Boehringer Ingelheim Pharmaceuticals, Inc.

    Faculty: Fernando Holguin, MD, MPH
    Professor of Medicine
    Pulmonary Sciences and Critical Care
    University of Colorado
    Aurora, CO

    Financial Disclosure:
    Nothing to disclose.

  • Target Audience

    This activity is designed to meet the educational needs of pulmonologist, allergist, primary care physicians and allied health professionals

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the key differences between type 2 and non-type 2 asthma.
    • Review advanced treatment options in non-type 2 asthma including the role of macrolides and bronchial thermoplasty.
    • Recognize the link between obesity and asthma.
  • Accreditation and Credit Designation Statements

    Physician Credit
    The American College of Chest Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    The American College of Chest Physicians designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Credit
    Provider approved by the California Board of Registered Nursing, Provider Number 16433, for .25 contact hour.

    Nurse Practitioners
    The American Academy of Nurse Practitioners Certification Board (AANPCB) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCB for further guidelines.

    Physician Assistants
    American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of .25 Category 1 credits for completing this activity.

    Maintenance of Certification Statement
    Successful completion of this CME activity enables the participant to earn up to .25 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

    Upon successful completion of this course, CHEST will submit your completion data to ABIM via ACCME's Program and Activity Reporting System (PARS) for MOC points. Please allow 3-5 business days after claiming for points to be reflected on your ABIM record.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This educational activity is supported by an educational grant from GlaxoSmithKline. Supported by an educational grant from Genentech, a member of the Roche Group.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Recent advances in asthma therapy have included several new biologic agents that modify Th2-inflammatory pathways. Treatment guidelines have provided a framework for the treatment of patients with Th2-mediated allergic asthma. However, approximately half of asthmatic patients do not fall within the Th2 inflammatory paradigm. Cinicians must be knowledgeable of treatment options and the role of potential novel therapies for this subgroup of patients.

  • Disclosure of Conflicts of Interest

    CHEST remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any relevant financial relationships that create a conflict of interest. It is not the intent of CHEST to disqualify anyone from participating in this educational activity, but to resolve any conflicts of interest that may arise from financial relationships with commercial interests. All conflicts of interest are reviewed by the educational activity course director/chair, the Education Committee, and/or the Professional Standards Committee to ensure that such situations are properly evaluated and, if necessary, resolved. CHEST educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all CHEST CME activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relevant financial relationships will be made available on-site during all educational activities.

    The following faculty members of this activity have disclosed to CHEST that they have a relevant financial relationship with a commercial interest as it relates to the activity:

    Host: Sandhya Khurana, MD, FCCP
    Professor of Medicine
    Division of Pulmonary & Critical Care Medicine
    Director, Mary Parkes Center for Asthma, Allergy & Pulmonary Care
    University of Rochester,
    Rochester, NY

    Financial Disclosure:
    Grant/Research Support: GlaxoSmithKline, AstraZeneca Pharmaceuticals LP, Sanofi; Editorial Support: Boehringer Ingelheim Pharmaceuticals, Inc.

    Faculty: Fernando Holguin, MD, MPH
    Professor of Medicine
    Pulmonary Sciences and Critical Care
    University of Colorado
    Aurora, CO

    Financial Disclosure:
    Nothing to disclose.

  • Target Audience

    This activity is designed to meet the educational needs of pulmonologist, allergist, primary care physicians and allied health professionals

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the key differences between type 2 and non-type 2 asthma.
    • Review advanced treatment options in non-type 2 asthma including the role of macrolides and bronchial thermoplasty.
    • Recognize the link between obesity and asthma.
  • Accreditation and Credit Designation Statements

    Physician Credit
    The American College of Chest Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    The American College of Chest Physicians designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Credit
    Provider approved by the California Board of Registered Nursing, Provider Number 16433, for .25 contact hour.

    Nurse Practitioners
    The American Academy of Nurse Practitioners Certification Board (AANPCB) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCB for further guidelines.

    Physician Assistants
    American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of .25 Category 1 credits for completing this activity.

    Maintenance of Certification Statement
    Successful completion of this CME activity enables the participant to earn up to .25 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

    Upon successful completion of this course, CHEST will submit your completion data to ABIM via ACCME's Program and Activity Reporting System (PARS) for MOC points. Please allow 3-5 business days after claiming for points to be reflected on your ABIM record.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This educational activity is supported by an educational grant from GlaxoSmithKline. Supported by an educational grant from Genentech, a member of the Roche Group.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/2/20